Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of 2007-2008 Fluvrin influenza vaccine in non-elderly and elderly adults
2007-002063-27Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2007
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of influenza a virus a/singapore/gp1908/2015 ivr-180 (h1n1) antigen (uv, formaldehyde inactivated) in influenza (2 arms), sponsored by Novartis. Primary endpoints: Hemagglutination inhibition antibody response for each influenza antigen at 21 days post-immunization and Safety after a single intramuscular injection of FLUVIRIN. Started Jun 2007; status: completed.
02
Drugs
influenza a virus a/singapore/gp1908/2015 ivr-180 (h1n1) antigen (uv, formaldehyde inactivated)
03
Conditions
influenza
Beyond the preview
Go deeper on 2007-002063-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002063-27.